These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

130 related items for PubMed ID: 10459811

  • 1. In-vitro interactions of itraconazole with flucytosine against clinical isolates of Cryptococcus neoformans.
    Barchiesi F, Gallo D, Caselli F, Di Francesco LF, Arzeni D, Giacometti A, Scalise G.
    J Antimicrob Chemother; 1999 Jul; 44(1):65-70. PubMed ID: 10459811
    [Abstract] [Full Text] [Related]

  • 2. In vitro interaction of flucytosine with conventional and new antifungals against Cryptococcus neoformans clinical isolates.
    Schwarz P, Dromer F, Lortholary O, Dannaoui E.
    Antimicrob Agents Chemother; 2003 Oct; 47(10):3361-4. PubMed ID: 14506059
    [Abstract] [Full Text] [Related]

  • 3.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 4.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 5.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 6.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 7.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 8. Evaluation of antifungal combination against Cryptococcus spp.
    Reichert-Lima F, Busso-Lopes AF, Lyra L, Peron IH, Taguchi H, Mikami Y, Kamei K, Moretti ML, Schreiber AZ.
    Mycoses; 2016 Sep; 59(9):585-93. PubMed ID: 27135278
    [Abstract] [Full Text] [Related]

  • 9.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 10. In vitro interaction of terbinafine with itraconazole, fluconazole, amphotericin B and 5-flucytosine against Aspergillus spp.
    Mosquera J, Sharp A, Moore CB, Warn PA, Denning DW.
    J Antimicrob Chemother; 2002 Aug; 50(2):189-94. PubMed ID: 12161398
    [Abstract] [Full Text] [Related]

  • 11.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 12.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 13. Susceptibility profile and epidemiological cut-off values of Cryptococcus neoformans species complex from Argentina.
    Córdoba S, Isla MG, Szusz W, Vivot W, Altamirano R, Davel G.
    Mycoses; 2016 Jun; 59(6):351-6. PubMed ID: 26865081
    [Abstract] [Full Text] [Related]

  • 14.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 15. In vitro activity of amphotericin B and itraconazole in combination with flucytosine, sulfadiazine and quinolones against Exophiala spinifera.
    Vitale RG, Afeltra J, de Hoog GS, Rijs AJ, Verweij PE.
    J Antimicrob Chemother; 2003 May; 51(5):1297-300. PubMed ID: 12697648
    [Abstract] [Full Text] [Related]

  • 16. In vitro susceptibility of Cryptococcus neoformans clinical isolates from Egypt to seven antifungal drugs.
    Abdel-Salam HA.
    Mycoses; 2005 Sep; 48(5):327-32. PubMed ID: 16115103
    [Abstract] [Full Text] [Related]

  • 17. Use of Pinus sylvestris L. (Pinaceae), Origanum vulgare L. (Lamiaceae), and Thymus vulgaris L. (Lamiaceae) essential oils and their main components to enhance itraconazole activity against azole susceptible/not-susceptible Cryptococcus neoformans strains.
    Scalas D, Mandras N, Roana J, Tardugno R, Cuffini AM, Ghisetti V, Benvenuti S, Tullio V.
    BMC Complement Altern Med; 2018 May 03; 18(1):143. PubMed ID: 29724221
    [Abstract] [Full Text] [Related]

  • 18.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 19.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 20. Combination of 5-flucytosine and capsule-binding monoclonal antibody in the treatment of murine Cryptococcus neoformans infections and in vitro.
    Feldmesser M, Mukherjee J, Casadevall A.
    J Antimicrob Chemother; 1996 Mar 03; 37(3):617-22. PubMed ID: 9182119
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 7.